2型糖尿病药物治疗的获益与危害:随机对照试验的系统评价与网络Meta分析
该系统评价与网络Meta分析纳入816项随机对照试验、471038例2型糖尿病成人患者,评估13类降糖药物与标准治疗相比的获益与危害,证据确定性采用GRADE分级。SGLT-2抑制剂(OR 0.88,95%CI 0.83-0.94;高确定性)和GLP-1受体激动剂(OR 0.88,95%CI 0.82-0.93;高确定性)降低全因死亡;非甾体类盐皮质激素受体拮抗剂(目前仅非奈利酮在慢性肾病患者中测试)可能降低死亡率(OR 0.89,95%CI 0.79-1.00;中等确定性)。研究确认SGLT-2抑制剂和GLP-1受体激动剂在降低心血管死亡、非致死性心肌梗死、心力衰竭住院和终末期肾病方面的获益;非奈利酮可能降低心力衰竭住院和终末期肾病,并可能降低心血管死亡。仅GLP-1受体激动剂降低非致死性卒中;SGLT-2抑制剂在降低终末期肾病方面优于其他药物。GLP-1受体激动剂以及可能SGLT-2抑制剂和替尔泊肽改善生活质量。危害大多具有药物类别特异性(如SGLT-2抑制剂的生殖器感染、替尔泊肽和GLP-1受体激动剂的严重胃肠道不良事件、非奈利酮导致住院的高钾血症)。替尔泊肽可能带来最大体重下降(平均差-8.57 kg;中等确定性);基础胰岛素(平均差2.15 kg;中等确定性)和噻唑烷二酮类(平均差2.81 kg;中等确定性)可能带来最大体重增加。SGLT-2抑制剂、GLP-1受体激动剂和
要点
- SGLT-2抑制剂降低全因死亡(OR 0.88,95%CI 0.83-0.94;高确定性),GLP-1受体激动剂同样降低全因死亡(OR 0.88,95%CI 0.82-0.93;高确定性)。
- 非甾体类盐皮质激素受体拮抗剂(目前仅非奈利酮在慢性肾病患者中测试)可能降低死亡率(OR 0.89,95%CI 0.79-1.00;中等确定性)。
- 仅GLP-1受体激动剂降低非致死性卒中;SGLT-2抑制剂在降低终末期肾病方面优于其他药物。
- 替尔泊肽可能带来最大体重下降(平均差-8.57 kg;中等确定性);基础胰岛素(平均差2.15 kg)和噻唑烷二酮类(平均差2.81 kg)可能带来最大体重增加(均为中等确定性)。
- 危害具有类别特异性:SGLT-2抑制剂的生殖器感染、替尔泊肽和GLP-1受体激动剂的严重胃肠道不良事件、非奈利酮导致住院的高钾血症。
适用人群与场景
- 成人2型糖尿病患者;纳入的随机对照试验随访24周或更长。
- 排除:系统比较一种以上药物类别联合与无药物的试验、随机对照试验的亚组分析、非英语研究。
红旗征与不能漏的情况
- SGLT-2抑制剂相关生殖器感染。
- 替尔泊肽和GLP-1受体激动剂相关严重胃肠道不良事件。
- 非奈利酮相关高钾血症导致住院。
研究设计与关键结果
- 系统评价与网络Meta分析纳入816项随机对照试验、471038例患者,评估13种药物类别;所有估计均与标准治疗比较。
- SGLT-2抑制剂降低全因死亡(OR 0.88,95%CI 0.83-0.94;高确定性);GLP-1受体激动剂降低全因死亡(OR 0.88,95%CI 0.82-0.93;高确定性);非甾体类盐皮质激素受体拮抗剂(目前仅非奈利酮在慢性肾病患者中测试)可能降低死亡率(OR 0.89,95%CI 0.79-1.00;中等确定性);其他药物可能不降低死亡率。
- SGLT-2抑制剂和GLP-1受体激动剂降低心血管死亡、非致死性心肌梗死、心力衰竭住院和终末期肾病;非奈利酮可能降低心力衰竭住院和终末期肾病,并可能降低心血管死亡。
- 仅GLP-1受体激动剂降低非致死性卒中;SGLT-2抑制剂在降低终末期肾病方面优于其他药物。
- GLP-1受体激动剂以及可能SGLT-2抑制剂和替尔泊肽改善生活质量。
- 替尔泊肽可能带来最大体重下降(平均差-8.57 kg;中等确定性);基础胰岛素(平均差2.15 kg;中等确定性)和噻唑烷二酮类(平均差2.81 kg;中等确定性)可能带来最大体重增加。
- SGLT-2抑制剂、GLP-1受体激动剂和非奈利酮的绝对获益随基线心血管和肾脏风险而变化。
证据类型、等级与局限
- 证据类型:系统评价与网络Meta分析,证据确定性采用GRADE分级。
- 高确定性:SGLT-2抑制剂和GLP-1受体激动剂降低全因死亡。
- 中等确定性:非奈利酮可能降低死亡率;替尔泊肽可能带来最大体重下降;基础胰岛素和噻唑烷二酮类可能带来最大体重增加;非奈利酮可能降低心力衰竭住院和终末期肾病,并可能降低心血管死亡;GLP-1受体激动剂以及可能SGLT-2抑制剂和替尔泊肽改善生活质量。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现强调需要持续评估科学进展,以便在2型糖尿病患者的临床实践指南中引入前沿更新。
指南或共识出处
- PROSPERO注册号CRD42022325948。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options.
DESIGN: Systematic review and network meta-analysis.
DATA SOURCES: Ovid Medline, Embase, and Cochrane Central up to 14 October 2022.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach.
RESULTS: The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference -8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (https://matchit.magicevidence.org/230125dist-diabetes).
CONCLUSIONS: This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022325948.
参考来源
- Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023. PMID: 37024129. doi:10.1136/bmj-2022-074068
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。